Picture of Avid Bioservices logo

CDMO — Avid Bioservices News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapNeutral

Avid Bioservices Inc expected to post earnings of 1  cent a share - Earnings Preview

* Avid Bioservices Inc  CDMO.OQ   CDMO.O  is expected
to show a
rise in quarterly revenue when it reports  results on June 29. 
    * The Tustin California-based  company is expected to report
 a
4.9% increase in revenue to $28.958 million from $27.61 million
a year ago, according to the mean estimate from 4 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Avid Bioservices
Inc is
for earnings of 1 cent per share. For the same quarter last
year, the company reported a loss of 4 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Avid
Bioservices
Inc is $30​, above​ its last closing price of $15.61. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jan. 31 2022  0.05        0.04       0.04      Met     0
 Oct. 31 2022  0.03        0.03       0.06      Beat    140
 Jul. 31 2021  0.04        0.04       0.10      Beat    166.7​
 Apr. 30 2021  0.00        0.01       -0.04     Missed  -900
 ​​Jan.        -0.03       -0.03      0.01      Beat    133.3
 31 2021                                                
 Oct. 31 2020  -0.05       -0.06      0.01      Beat    117.6​
 Jul. 31 2020  -0.07       -0.07      0.06      Beat    180
 Apr. 30 2020  -0.17       -0.16      -0.11     Beat    32.7
 This summary was machine generated June 27 at 20:06 GMT.  All
figures in US dollars  unless otherwise stated

Recent news on Avid Bioservices

See all news